Search Within

Gynecology Disease Management Team

Formats
  1. Journal Article (2473)
  2. Meeting Abstract (2112)
  3. Book Section (226)
  4. Review (135)
  5. Editorial (88)
  6. Guidelines (39)
  7. Correspondence (19)
  8. Conference Paper (16)
  9. Miscellaneous (13)
  10. Research Letter (12)
  11. Book Whole (11)
Groups
  1. Surgery (2362)
  2. Department of Medicine (2268)
  3. Solid Tumor Oncology Division (2217)
  4. GDMT, Surgery (1974)
  5. GDMT, Medicine (1910)
  6. Gynecologic Medicine Service (1877)

More Groups

People
  1. Nadeem Abu-Rustum (902)
  2. Robert Soslow (797)
  3. Dennis Chi (716)
  4. Britta Weigelt (646)
  5. Carol Aghajanian (615)
  6. Mario Leitao (582)

More People

Years
  1. 2025 (161)
  2. 2024 (308)
  3. 2023 (332)
  4. 2022 (361)
  5. 2021 (308)
  6. 2020 (356)

More Years

Publications
  1. Gynecologic Oncology (950)
  2. Journal of Clinical Oncology (543)
  3. Modern Pathology (354)
  4. International Journal of Gynecological Cancer (321)
  5. Laboratory Investigation (311)
  6. International Journal of Radiation Oncology, Biology, Physics (223)

More Publications

Publishers
  1. Elsevier B.V. (1001)
  2. American Society of Clinical Oncology (598)
  3. Lippincott Williams & Wilkins (584)
  4. Elsevier Inc. (481)
  5. Nature Publishing Group (424)
  6. Nature Research (356)

More Publishers

Results (5144)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2 study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer
    Meeting Abstract

    Van Nieuwenhuysen, E.; Bouberhan, S.; Papadimitriou, K.; Arend, R. C.; Lee, J. Y.; O'Cearbhaill, R. E.; O'Malley, D. M.; You, B.; Martin, A. G.; Michels, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase I/II, first-in-human study of VLS-1488, an oral KIF18A inhibitor, in patients with advanced cancer
    Meeting Abstract

    Gaillard, S.; Starodub, A.; O'Neil, B.; Mathews, C. A.; Dumbrava, E. E.; Friedman, C. F.; Swiecicki, P.; Oh, C.; Andreu, C.; Lee, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2, open-label, single-arm, prospective, multicenter study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer
    Meeting Abstract

    Dockery, L. E.; Slomovitz, B. M.; Musa, F.; Mathews, C. A.; Priebe, A. M.; Green, A.; Puechl, A.; Birrer, M. J.; Spirtos, N. M.; Ding, L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, first-in-human study of CUSP06, a cadherin-6 (CDH6) -directed antibody-drug conjugate, in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors
    Meeting Abstract

    Spira, A. I.; Lee, E. K.; O'Cearbhaill, R. E.; LoRusso, P.; Falchook, G. S.; Patel, M. R.; Richardson, D. L.; Lu, W.; Marreddy, P.; Farrington, D. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I/II first-in-human study to evaluate the safety and efficacy of tissue factor-ADC MRG004A in patients with solid tumors
    Meeting Abstract

    Park, W.; Zhang, J.; Dayyani, F.; Shan, J.; Liu, R.; Guo, R.; O'Reilly, E. M.; Liu, Z.; Gao, S.; Wu, X.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • CCNE1 amplification as marker of poor prognosis and novel therapeutic target in advanced breast cancer
    Meeting Abstract

    Marra, A.; Selenica, P.; Zhu, Y.; Safonov, A.; Razavi, P.; Roulston, A.; Koehler, M.; Curigliano, G.; Ross, D. S.; Weigelt, B.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab
    Meeting Abstract

    Kyi, C.; Van Dongen, M.; Rottey, S.; Bermejo, I. M.; Mittag, D.; Gouveia, D.; Bol, K.; Yan, C.; Joe, A. K.; Laus, G.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC)
    Meeting Abstract

    Jazaeri, A. A.; Grisham, R. N.; Gaillard, S.; How, J. A.; Hazard, S.; Musso, L.; Kyi, C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
    Meeting Abstract

    Traina, T. A.; Chen, Y.; Khoury, K.; Rugo, H. S.; Mayer, E. L.; Carey, L. A.; Melisko, M. E.; Syldor, A.; Friedman, C.; Savoie, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Endometrial carcinoma in Black vs Asian women: Racial disparities and opportunities to improve survival in 219,301 patients in the USA
    Meeting Abstract

    Becerra, H. A.; Ilerhunmwuwa, N. P.; Wasifuddin, M.; Uche, I.; Osorio, J. C.; Wang, J. C. C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save